105 related articles for article (PubMed ID: 15591726)
1. Why institutions do not participate in ovarian cancer trials -- results from a survey in Germany.
Sehouli J; Kostromitskaia J; Stengel D; du Bois A
Onkologie; 2005 Jan; 28(1):13-7. PubMed ID: 15591726
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
4. Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.
Gencer D; Tauchert F; Keilhauer N; Al-Batran SE; Stahl M; Oskay-Özcelik G; Hipp M; Leibbrand B; Prasnikar N; Trarbach T; Stoll C; van Kampen M; Hochhaus A; Lorenzen S; Hofheinz RD
Onkologie; 2011; 34(8-9):435-40. PubMed ID: 21934343
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of women with gynecologic cancer who enter clinical trials.
Luck MB; McIntire M; Blades N; Robinson W
J Reprod Med; 2005 Jul; 50(7):481-5. PubMed ID: 16130843
[TBL] [Abstract][Full Text] [Related]
6. Stop the pain! A nation-wide quality improvement programme in paediatric oncology pain control.
Zernikow B; Hasan C; Hechler T; Huebner B; Gordon D; Michel E
Eur J Pain; 2008 Oct; 12(7):819-33. PubMed ID: 18222100
[TBL] [Abstract][Full Text] [Related]
7. [Impact of center characteristics on outcome in ovarian cancer in Germany].
du Bois A; Rochon J; Lamparter C; Pfisterer J
Zentralbl Gynakol; 2005 Feb; 127(1):18-30. PubMed ID: 15702447
[TBL] [Abstract][Full Text] [Related]
8. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
9. [The Quality Assurance Program of the AGO Organkommission OVAR (QS-OVAR): Pattern of Care and Reality in Germany 2001].
du Bois A; Rochon J; Lamparter C; Pfisterer J
Zentralbl Gynakol; 2005 Feb; 127(1):9-17. PubMed ID: 15702446
[TBL] [Abstract][Full Text] [Related]
10. [Breast cancer: analysis of treatment quality in Germany 2004: retrospective survey by Arbeitsgemeinschaft Gynäkologische Onkologie (AGO)].
Jackisch C; Untch M; Chatsiproios D; Lamparter C; Overkamp F; Lichtenegger W; Rönsberg W; Thomssen C; von Minckwitz G
Zentralbl Gynakol; 2006 Dec; 128(6):352-61. PubMed ID: 17213975
[TBL] [Abstract][Full Text] [Related]
11. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
12. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials.
Townsley CA; Chan KK; Pond GR; Marquez C; Siu LL; Straus SE
BMC Cancer; 2006 Feb; 6():34. PubMed ID: 16466574
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO].
Schmalfeldt B; du Bois A; Burges A; Emons G; Fink D; Gropp M; Hasenburg A; Jäger W; Kimmig R; Kiechle M; Kommoss F; Kreienberg R; Kuhn W; Lück HJ; Meier W; Münstedt K; Ortmann O; Pfisterer J; Richter B; Runnebaum I; Schröder W; Sehouli J; Tanner B; Wagner U; Weis J
Zentralbl Gynakol; 2006 Feb; 128(1):11-7. PubMed ID: 16450281
[TBL] [Abstract][Full Text] [Related]
14. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?
Carney ME; Lancaster JM; Ford C; Tsodikov A; Wiggins CL
Gynecol Oncol; 2002 Jan; 84(1):36-42. PubMed ID: 11748973
[TBL] [Abstract][Full Text] [Related]
16. Who refuses enrollment in cardiac clinical trials?
Sen Biswas M; Newby LK; Bastian LA; Peterson ED; Sugarman J
Clin Trials; 2007; 4(3):258-63. PubMed ID: 17715252
[TBL] [Abstract][Full Text] [Related]
17. Levels of knowledge and perceived understanding among participants in cancer clinical trials - factors related to the informed consent procedure.
Bergenmar M; Johansson H; Wilking N
Clin Trials; 2011 Feb; 8(1):77-84. PubMed ID: 21109583
[TBL] [Abstract][Full Text] [Related]
18. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study.
Moore DH; Kauderer JT; Bell J; Curtin JP; Van Le L
Gynecol Oncol; 2004 Aug; 94(2):368-74. PubMed ID: 15297174
[TBL] [Abstract][Full Text] [Related]
19. Gynecologic Oncology Group quality assurance audits: analysis and initiatives for improvement.
Blessing JA; Bialy SA; Whitney CW; Stonebraker BL; Stehman FB
Clin Trials; 2010 Aug; 7(4):390-9. PubMed ID: 20576671
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
